Glenmark responds to DCGI letter seeking clarification on Fabiflu

Jul 21, 2020

Mumbai (Maharashtra) [India] July 21 (ANI/PRNewswire): In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.
PDF: https://mma.prnewswire.com/media/1217258/Glenmark_Response_DCGI.pdf
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)